EMA quizzed over Humira trial data redactions
This article was originally published in Scrip
Executive Summary
The European Ombudsman has written to the European Medicines Agency expressing concern over some of the information the EMA agreed to remove from AbbVie's clinical study reports for the blockbuster drug Humira before making them publicly available.